Miguel Seabra stepped down from the presidency of Portugal's science funding agency. Although Seabra invoked "personal reasons" for his decision, scientists note that he resigned amid mounting criticism of the agency's policies.

'Premature' rules for preclinical research need more flexibility and greater community involvement, say scientific society leaders.

Germany's ruling political parties have agreed to plough €5 billion (US$5.4 billion) more into science from 2018 to 2028.

The European Parliament has thrown a spanner into the works of Juncker's plan to slash €2.7 billion from the EU's 2014 to 2020 research budget for a new investment fund to help ramp up Europe's economy.

Rumours of germline modification prove true — and look set to reignite an ethical debate.

The $3-million state initiative will coordinate with a national effort to promote individualized patient treatment.

Nature Biotechnology asks peer reviewers to check accessibility of code used in computational studies.

Nature readers favour creating more secure jobs to fix science’s broken postdoctoral system.

Problems plague EU Medical Research Initiative.

ORCID has been awarded an 18-month, $3 million grant by The Leona M. and Harry B. Helmsley Charitable Trust to develop the infrastructure and capacity to support international adoption and technical integration of ORCID identifiers.

Institutional public access plans for Open Science.

There is a growing number of postdocs and few places in academia for them to go. But change could be on the way.

THE analysis reveals progress in closing gap, but female academics still earn nearly £6K less than men.

World University Rankings analysis reveals the biggest climbers under 50 years of age.

Over 20 European Universities (LERU) signed the DORA Declaration on Research Assessment.

An editor of Nature Publishing Group has resigned in a very public protest the recent decision to allow authors to pay money to expedite peer review of their submitted papers.

Ryoji Noyori, long-time president of Japan's RIKEN network of basic-research laboratories, has resigned after a year in which the organization was embroiled in controversy over fraudulent stem-cell papers.

Harold Varmus, a Nobel Prize winner who has led the National Cancer Institute at the NIH for nearly 5 years, said he will step down from his post effective at the end of this month.

BioMed Central is retracting 43 papers possibly involving third-party companies selling the service.

HHMI, the Bill & Melinda Gates Foundation, and the Simons Foundation launch Faculty Scholars Program to give promising early-career scientists a boost.

The first of a number of independent reviews of the policy during the transition period (five years from the policy being introduced), and covers the first 16 months, April 2013 to July 1014, of the policy’s implementation.

Swiss researchers who work in the US are having trouble keeping their bank accounts in Switzerland due to complications from long-standing tax evasion issues between the two countries.

The next president of the Royal Society will be the Nobel-winning Cambridge researcher Prof Sir Venki Ramakrishnan. He will succeed geneticist Sir Paul Nurse in December 2015.

Ukraine will now be able to fully participate in Horizon 2020 on equal terms with EU Member States and other associated countries.

Personal genetics firm 23andMe has revealed it is to launch a new drug discovery and development division.

Wiley is piloting a partnership with Publons to give you official recognition for your peer review work. This partnership means you can opt-in to have your reviews for participating Wiley journals automatically added to your reviewer profile on Publons.

Scientific journal articles will become freely available, thanks to new policies at major U.S. science agencies.

The HBP should be remade into an international organization modeled on CERN or the EMBL in Heidelberg, says a panel formed to unite the neuroscience community.

Nature is offering anonymity for both reviewer and reviewed, but questions remain about value and effectiveness of the approach.

Giving equal weight to everybody’s opinion might be the worse thing you could do.